Skip to content
value.today

Universe Pharmaceuticals INC

UPC
$28 Mmarket cap on Aug 1, 2026+366.7% since Jan 2024
Compare
World rank
#23,240
Revenue
$17.9 B
For year ending September-2025
Net income
$-3.7 B
-20.6% margin
SEC filing
Employees
69
As of September 30, 2025
SEC filing

Universe Pharmaceuticals INC in brief

Universe Pharmaceuticals INC is a listed company in the Biotechnology industry, based in China. It was founded in 2019. Its market value was $28 M on 1 August 2026, which makes it the 23,240th largest listed company in the world and the 4,206th largest in China on this site. In the year to September 2025 it had sales of $17.9 B and a net loss of $3.7 B. It employs about 69 people and Gang Lai is its chief executive. Its largest product and service lines by sales in 2025 were Revenue from sales of self-manufactured TCMD products (74%) and Revenue from sales of third-party products (26%). Its shares trade under the symbol UPC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Universe Pharmaceuticals INC

As we introduce new products to our customers, we may be required to comply with additional laws and regulations that are yet to be determined. To comply with such additional laws and regulations, we may be required to obtain necessary certificates, licenses or permits, as well as expend additional resources to monitor regulatory and policy developments. Our failure to adequately comply with such additional laws and regulations may delay, or possibly prevent, some of our products from being offered to customers, which may have a material adverse effect on our business, financial condition and results of operations.

From the company's annual report filed with the US SEC: read the report

Universe Pharmaceuticals INC timeline

7 events, 2019–2023
  1. 2019
  2. 🏁
    · approximate
    Founded
  3. 2020
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 💰
    Record net income of $11 million
    FY2021, the highest profit of the 3 years on record.
  7. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 24 March 2021; shares registered for exchange trading on 17 March 2021.
  8. 2023
  9. 💰
    Revenue passed $1 billion
    FY2023 revenue of $32.3 billion, up from $40 million in FY2022.
  10. 💰
    Revenue passed $10 billion
    FY2023 revenue of $32.3 billion, up from $40 million in FY2022.
  11. 💰
    Record revenue of $32.3 billion
    FY2023, the highest of the 7 years on record.

Events of Universe Pharmaceuticals INC from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$13 M$25 M$38 M$51 M2023202420252026

World rank over time

▲ up 6,642 places since 2022
2022-01-07: #27646#27,64620222022-12-25: #26857#26,85720222023-07-30: #25579#25,57920232024-01-05: #32073#32,07320242026-03-08: #13544#13,54420262026-08-01: #21004#21,0042026

Rank in China: #4,973 (Jan 2022) · #5,156 (Dec 2022) · #5,172 (Jul 2023) · #5,450 (Jan 2024) · #4,502 (Mar 2026) · #4,227 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.0×
Price / book
0.0×
Free cash flow yield
-18996.8%
Net margin (TTM)
-20.6%
Operating margin
-16.3%
Return on equity
-6.5%
Liabilities / assets
19.0%
Revenue growth
-22.4%
R&D / revenue
3.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2019: revenue $33M, net income $8M$33MFY19Fiscal year ending Sep 2020: revenue $31M, net income $8M$31MFY20Fiscal year ending Sep 2021: revenue $48M, net income $11M$48MFY21Fiscal year ending Sep 2022: revenue $40M, net income $-8M$40MFY22Fiscal year ending Sep 2023: revenue $32.3B, net income $-6.6B$32.3BFY23Fiscal year ending Sep 2024: revenue $23.0B, net income $-8.7B$23.0BFY24Fiscal year ending Sep 2025: revenue $17.9B, net income $-3.7B$17.9BFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025$17.9B-22.4%$-2.9B$-3.7B-20.6%
Sep 2024$23.0B-28.7%$-8.0B$-8.7B-37.9%
Sep 2023$32.3B+80390.1%$-4.0B$-6.6B-20.4%
Sep 2022$40M-16.3%$-7M$-8M-19.7%
Sep 2021$48M+56.3%$14M$11M23.6%
Sep 2020$31M-7.6%$10M$8M24.6%
Sep 2019$33M—$10M$8M22.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-5.1B$267M$-5.3B$-8.06—
Sep 2024$-9.5B$208M$-9.7B$-626.96—
Sep 2023$1.1B$44M$1.1B$-1089.21—
Sep 2022$-1M$0M$-1M$-1309.11—
Sep 2021$-2M$0M$-3M$3.58—
Sep 2020$6M$0M$6M$0.47—
Sep 2019$13M$0M$13M$0.47—

SEC filings

Official filings of Universe Pharmaceuticals INC with the US Securities and Exchange Commission.

Annual results

Revenue
$17.9 B
Operating income
$-2.9 B
Net income
$-3.7 B

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$69.3 B
Total liabilities
$13.2 B
Total equity
$56.1 B

As of September-2025

Top 7 institutional investors in Universe Pharmaceuticals INC#

As of Sep 30, 2026
7 institutions held 78,172 shares (about 0.9% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 7 largest institutional investors in Universe Pharmaceuticals INC
#InstitutionShares heldChange (shares)% heldValueFiled
1Geode Capital Management, LLC44,531New0.50%$0 MNov 6, 2026
2Citadel Advisors LLC14,625New0.17%$0 MNov 16, 2026
3Jane Street Group, LLC11,292New0.13%$0 MNov 12, 2026
4Osaic Holdings, Inc.6,1720 (0.00%)0.07%$0 MNov 12, 2026
5UBS Group AG1,550-12,817 (-89.21%)0.02%$0 MNov 10, 2026
6National Bank Of Canada /fi/1New0.00%$0 MNov 16, 2026
7Caitong International Asset Management Co., Ltd1-11 (-91.67%)0.00%$0 MOct 29, 2026

Insider trading at Universe Pharmaceuticals INC#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
0
0 purchases, 0 insiders
Sold, 12 months
0
0 sales, 0 insiders
Net, 12 months
0
open market only
Insiders on file
1
since
Universe Pharmaceuticals INC: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gang LaiChief Executive Officer, Director, 10% ownerGrant or award+71,890——local71,890Form 4
filed Gang LaiChief Executive Officer, Director, 10% ownerGrant or award+12,610——local12,610Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: Universe Pharmaceuticals INC#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
41,937
7.4% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-09-02 13:34 UTC, code LUDP, resumed 13:39 UTC
  • 2026-06-29 13:31 UTC, code LUDP, resumed 13:36 UTC
  • 2026-04-23 13:30 UTC, code LUDP, resumed 13:40 UTC
  • 2025-12-26 17:37 UTC, code LUDP, resumed 17:42 UTC
  • 2025-12-26 16:03 UTC, code LUDP, resumed 16:08 UTC

Fails to deliver

  • : 1,352 shares at $1.93
  • : 866 shares at $2.24
  • : 2,419 shares at $4.30
  • : 1,412 shares at $3.98
  • : 1,598 shares at $4.27

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Universe Pharmaceuticals INC scorecard#

Passes 3 of the 13 checks that could be worked out: strongest in profitability (2 of 5), weakest in growth (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 4
    • ✗Revenue grew in the newest year-22.4%Revenue down 22.4% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-8.06 vs -626.96Diluted EPS -8.06 in fiscal 2025 against -626.96 the year before (report's currency).
    • ✗Net income higher than five years earlier-$3.7 B-$3.7 B in fiscal 2025 against $8 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$3.7 BNet income -$3.7 B in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-16.3%-16.3% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-7.2%-7.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-16.3%-16.3% in fiscal 2025 against -17.5% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities4.1×Current ratio 4.07 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-10.1×Operating income -10.1 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone0.54Z-score 0.54 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Universe Pharmaceuticals INC's statements, beside the median of Biotechnology.

Universe Pharmaceuticals INC: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-16.3%-60.5%
Net margin-20.6%-68.9%
Return on equity-7.2%-61.0%
Revenue growth-22.4%15.8%
Free cash flow margin-29.8%-61.5%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 22.4% against the year before.
  • Net loss of $3.7 billion, the 4th loss-making year in a row.
  • Free cash flow was negative: -$5.3 billion.
  • Operating income covers the interest bill only -10.1 times.

Universe Pharmaceuticals INC: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Universe Pharmaceuticals INC: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019
Income statement
Revenue17,85923,024r32,309r40483133
Cost of revenue11,55816,953r21,994r18231720
Gross profit6,3016,072r10,315r22251413
Research and development6723,031r4,859r7.65.50.60.6
Selling and marketing4,7988,171r6,784r193.01.61.6
General and administrative3,7482,890r2,639r2.2r3.31.71.5
Operating expenses9,21714,092r14,281r29r123.83.7
Operating income−2,916−8,020r−3,966r−7.0r14109.8
Interest expense and finance costs289305r190r0.20.10.10.1
Share of profit of associates6532r31r0.00.00.00.0
Other non-operating income (expense)−756−101r−361r−0.1r0.1−0.2−0.1
Income before tax−3,672−8,121r−4,327r−7.1r14109.7
Income tax—607r2,254r0.8r2.42.52.1
Net income including minority interests———−8.7117.67.6
Net income attributable to shareholders−3,672−8,727r−6,581r−7.9r117.6—
Earnings per share, basic-8.06-626.96-1,089.21r-1,309.11r3.58r0.470.47
Earnings per share, diluted-8.06-626.96-1,089.21r-1,309.11r3.58r0.470.47
Shares, weighted average (basic)0.50.00.0r0.0r3.2r16—
Shares, weighted average (diluted)0.50.00.0r0.0r3.2r1616
Balance sheet
Cash and cash equivalents33,59229,498r5.35.78.1103.2
Short-term investments——131314——
Receivables13,00812,906r11r151611—
Inventory2,1931,737r3.32.22.51.9—
Other current assets40852r0.0r1.7———
Current assets53,60451,638r25r425023—
Property, plant and equipment3,5843,568r3.74.34.74.4—
Other intangible assets297263r0.10.20.1r0.2—
Investments in associates702712r702r0.7———
Non-current assets15,70016,316r16r18205.5—
Total assets69,30367,953r42r607029—
Accounts payable1,6704,915r4.6r3.15.32.7—
Debt due within a year2,107——————
Current liabilities13,17420,313r14r13118.0—
Non-current liabilities—2,137—————
Total liabilities13,17422,450r14————
Retained earnings−13,844−10,172r−1.4r162514—
Shareholders' equity56,13045,503r27,970r35,331r47r2112
Total liabilities and equity69,30367,953r42r607029—
Shares outstanding0.60.00.0r3.6r2216—
Cash-flow statement
Depreciation and amortization517486r509r0.50.40.40.4
Cash from operating activities−5,052−9,507r1,117r−1.3r−2.16.113
Capital expenditure−267−208r−44r−0.1−0.4−0.1−0.1
Intangible assets bought−80−117r—————
Cash from investing activities−342−361r−44r−3.9−27−0.1−0.1
Shares issued15,00025,000r—————
Dividends paid——————−16
Cash from financing activities9,72633,954r−1,391r3.3270.5−16
Exchange-rate effect on cash−238126r−108r−0.5r0.60.3−0.1
Change in cash4,09424,212r−426r−2.4−2.06.9−3.0
Report20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Universe Pharmaceuticals INC sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Revenue from sales of self-manufactured TCMD products$13.3 B74%
  • Revenue from sales of third-party products$4.6 B26%

Source: SEC annual report (XBRL data) · as of Sep 30, 2025

Where Universe Pharmaceuticals INC operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Universe Pharmaceuticals INC: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Universe Pharmaceuticals INC: countries of operation
CountryPresenceRevenue there
🇨🇳 ChinaHeadquarters1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

How Universe Pharmaceuticals INC compares in Biotechnology

  • Market cap$28 M · higher than 20% of 726
  • Revenue$17.9 B · highest of 647
  • Net margin-20.6% · higher than 60% of 408
  • Revenue growth-22.4% · higher than 29% of 438
  • Price / sales0.0× · lowest of 339
  • Price / book0.0× · lowest of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Universe Pharmaceuticals INC🇨🇳$28 M—-20.6%-22.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Employees:
As of September 30, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Universe Pharmaceuticals INC? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Universe Pharmaceuticals INC's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Universe Pharmaceuticals INC? Suggest a correction